Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy

International Journal of Radiation Oncology Biology Physics

Volumn 48, Issue 4, 2000, Pages 1097-1105

  Elconin, Joel H ^a   Roberts, Kenneth B ^b   Rizzieri, David A ^a   Vermont, Carmen ^a   Clough, Robert W ^a   Kim, Charlotte ^b   Dodge, Richard K ^a   Prosnitz, Leonard R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Combined modality therapy; Hodgkin's disease; Large mediastinal adenopathy; Radiation dose

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GALLIUM; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; FEMALE; HISTOLOGY; HODGKIN DISEASE; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM METASTASIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIATION DOSE; RECURRENCE RISK; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TREATMENT FAILURE; VINBLASTINE; VINCRISTINE;

EID: 0034333171     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00695-7     Document Type: Article

References (43)

1. The significance of mediastinal involvement in early stage Hodgkin's disease
2. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy; The Stanford experience
3. Prognosis of bulky Hodgkin's disease treated with chemotherapy alone or combined with radiotherapy
4. Hodgkin's disease with bulky mediastinal involvement; Effective management with combined modality therapy
5. Combined modality treatment for poor prognosis stage I and II Hodgkin's disease
6. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy; Ten year results of the Paris-Ouest-France 81/12 trial, including 262 patients
7. Stage IA-IIB Hodgkin's disease; Management and outcome of extensive thoracic involvement
8. Alternating MOPP and ABVD chemotherapy plus mantle-field radiotherapy in patients with massive mediastinal Hodgkin's disease
9. Combined modality therapy for advanced Hodgkin's disease; 15 year follow-up data
10. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy
11. Combined modality treatment with low dose radiation and MOPP chemotherapy for children with Hodgkin's disease
12. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate stage Hodgkin's disease
13. Mediastinal irradiation in combined modality therapy for Hodgkin's disease
14. Radiation following chemotherapy for mediastinal Hodgkin's disease; The outcome of various doses for bulky tumors
15. Radiation techniques for the treatment of Hodgkin's disease with combined modality therapy or radiation alone
16. Non-parametric estimation from incomplete observations
17. Regression models and life tables
18. The management of bulky mediastinal Hodgkin's disease
19. Supradiaphragmatic Hodgkin's disease; The significance of large mediastinal masses
20. Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy
21. An updated dose-response analysis in Hodgkin's disease
22. Hodgkin's disease; A reassessment of prognostic factors following modification of radiotherapy
23. Prognostic groups for management of localized Hodgkin's disease
24. Theoretical considerations in combinations of localized and systemic therapy for neoplastic disease
25. Low dose radiation therapy and combination chemotherapy in the treatment of advanced Hodgkin's disease
26. Comparison of high dose and low dose radiation with and without chemotherapy for children with Hodgkin's disease; An analysis of the experience at the Children's Hospital of Philadelphia and the Hospital of the University of Pennsylvania
27. Low dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease; The experience of the French Society of Pediatric Oncology
28. Efficacy and toxicity of multi-agent chemotherapy and low dose involved field radiotherapy in children and adolescents with Hodgkin's disease
29. Combined modality therapy for advanced Hodgkin's disease; 15 year follow-up data
30. Low dose involved field radiation after chemotherapy in advanced Hodgkin's disease; A Southwestern Oncology Group randomized study
31. An updated dose-response analysis in Hodgkin's disease
32. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease
33. Mantle irradiation in Hodgkin's disease
34. Late effects on pulmonary function of mantle field irradiation, chemotherapy or combined modality therapy for Hodgkin's disease
35. Prospective study of long-term pulmonary manifestations of mantle irradiation
36. Breast cancer and other second neoplasms after childhood Hodgkin's disease
37. Long-term follow up of patients treated with primary radiotherapy for supradiaphragmatic Hodgkin's disease at St. Jude Children's Research Hospital
38. Second cancers following pediatric Hodgkin's disease
39. Incidence of second cancers in patients treated for Hodgkin's disease
40. Risk of second primary cancers after Hodgkin's disease by type of treatment; Analysis of 2846 patients in the British National Lymphoma investigation
41. Second solid malignancies after combined modality therapy for Hodgkin's disease
42. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low dose radiation
43. Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease